All In Biotech

Drug Trial Radar · NCT07751250

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of Casdatifan (AB521) in Participants With Moderate Hepatic Impairment Compared to Healthy Matched Participants

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Aug 14, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.

Conditions

  • Healthy Participants
  • Hepatic Impairment

Interventions

  • CasdatifanDrug

    Participants will receive a 100 mg single oral dose of casdatifan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curve, from time 0 to the last observed non-zero concentration, of casdatifan in plasma (AUC0-t)Time frame: Up to 10 days post-dose
  2. Area under the concentration time curve from time 0 extrapolated to infinity of casdatifan in plasma (AUC0-inf)Time frame: Up to 10 days post-dose
  3. Maximum observed concentration of casdatifan in plasma (Cmax)Time frame: Up to 10 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.